These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 9531875)

  • 21. Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone.
    Cabrera RA; Stadtmauer L; Mayer JF; Gibbons WE; Oehninger S
    Fertil Steril; 2005 Jan; 83(1):42-8. PubMed ID: 15652885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection.
    Takeuchi S; Minoura H; Shibahara T; Tsuiki Y; Noritaka F; Toyoda N
    Fertil Steril; 2001 Sep; 76(3):532-7. PubMed ID: 11532477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful induction of ovulation and conception with combined gonadotropin-releasing hormone agonist plus highly purified follicle-stimulating hormone in patients with polycystic ovarian disease.
    Lanzone A; Fulghesu AM; Spina MA; Apa R; Menini E; Caruso A; Mancuso S
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1253-8. PubMed ID: 3119655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple follicular development and ovarian steroidogenesis following subcutaneous administration of a highly purified urinary FSH preparation in pituitary desensitized women undergoing IVF: a multicentre European phase III study.
    Howles CM; Loumaye E; Giroud D; Luyet G
    Hum Reprod; 1994 Mar; 9(3):424-30. PubMed ID: 8006130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value of suppression with a gonadotropin-releasing hormone agonist prior to gonadotropin stimulation for in vitro fertilization.
    Droesch K; Muasher SJ; Brzyski RG; Jones GS; Simonetti S; Liu HC; Rosenwaks Z
    Fertil Steril; 1989 Feb; 51(2):292-7. PubMed ID: 2492234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients.
    Smitz J; Andersen AN; Devroey P; Arce JC;
    Hum Reprod; 2007 Mar; 22(3):676-87. PubMed ID: 17110397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome.
    Gordon UD; Harrison RF; Fawzy M; Hennelly B; Gordon AC
    Fertil Steril; 2001 Feb; 75(2):324-31. PubMed ID: 11172834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of low day 3 luteinizing hormone levels on in vitro fertilization treatment outcome.
    Noci I; Maggi M; Fuzzi B; Biagiotti R; Ricci F; Marchionni M
    Gynecol Endocrinol; 2000 Oct; 14(5):321-6. PubMed ID: 11109971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison between prolactin, gonadotrophins and steroid hormones in serum and follicular fluid after stimulation with gonadotrophin-releasing hormone agonists and human menopausal gonadotrophin for an in-vitro fertilization programme.
    Kamel MA; Zabel G; Bernart W; Neulen J; Breckwoldt M
    Hum Reprod; 1994 Oct; 9(10):1803-6. PubMed ID: 7844206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The utility of a midcycle follicle-stimulating hormone boost in addition to human chorionic gonadotropin for timing of follicle aspiration in unstimulated in vitro fertilization cycles.
    Lindheim SR; Sauer MV; Francis MM; Macaso T; Lobo R; Paulson RJ
    Gynecol Obstet Invest; 1997; 43(2):76-8. PubMed ID: 9067710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Premature luteinization in in vitro fertilization cycles using gonadotropin-releasing hormone agonist (GnRH-a) and recombinant follicle-stimulating hormone (FSH) and GnRH-a and urinary FSH.
    Ubaldi F; Camus M; Smitz J; Bennink HC; Van Steirteghem A; Devroey P
    Fertil Steril; 1996 Aug; 66(2):275-80. PubMed ID: 8690116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome.
    Filicori M; Cognigni GE; Taraborrelli S; Spettoli D; Ciampaglia W; de Fatis CT; Pocognoli P
    J Clin Endocrinol Metab; 1999 Aug; 84(8):2659-63. PubMed ID: 10443656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy.
    Kolibianakis EM; Albano C; Kahn J; Camus M; Tournaye H; Van Steirteghem AC; Devroey P
    Fertil Steril; 2003 Apr; 79(4):873-80. PubMed ID: 12749423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initial estradiol response predicts outcome of exogenous gonadotropins using a step-down dose regimen for induction of ovulation in polycystic ovary syndrome.
    Schoot DC; Hop WC; de Jong FH; van Dessel TJ; Fauser BC
    Fertil Steril; 1995 Dec; 64(6):1081-7. PubMed ID: 7589656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. The European Recombinant Human LH Study Group.
    J Clin Endocrinol Metab; 1998 May; 83(5):1507-14. PubMed ID: 9589647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different follicle stimulating hormone/luteinizing hormone ratios for ovarian stimulation.
    Duijkers IJ; Vemer HM; Hollanders JM; Willemsen WN; Bastiaans LA; Hamilton CJ; Thomas CM; Borm GF
    Hum Reprod; 1993 Sep; 8(9):1387-91. PubMed ID: 8253923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of ovarian follicular and luteal function during treatment with exogenous gonadotropins in anovulatory infertility.
    Yuen BH; Sy L; Cannon W
    Am J Obstet Gynecol; 1981 Jul; 140(6):629-35. PubMed ID: 6167169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized comparative study of purified follicle stimulating hormone and human menopausal gonadotropin after pituitary desensitization with Buserelin for superovulation and in vitro fertilization.
    Bentick B; Shaw RW; Iffland CA; Burford G; Bernard A
    Fertil Steril; 1988 Jul; 50(1):79-84. PubMed ID: 3133251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Hormone profile and follicle development in ovarian stimulation treatment for in vitro fertilization. II. Prolactin, estradiol and progesterone profile].
    Sudik R; Fliess FR; Kunkel S
    Zentralbl Gynakol; 1989; 111(9):567-80. PubMed ID: 2500795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.